| Previous Close | 321.03 |
| Open | 320.92 |
| Bid | 320.05 x 2000 |
| Ask | 320.88 x 600 |
| Day's Range | 320.03 - 321.12 |
| 52 Week Range | 268.25 - 326.88 |
| Volume | 447,199 |
| Avg. Volume | 1,074,151 |
| Net Assets | 18B |
| NAV | 315.62 |
| PE Ratio (TTM) | N/A |
| Yield | 1.15% |
| YTD Return | 5.04% |
| Beta (3y) | 0.97 |
| Expense Ratio (net) | 0.25% |
| Inception Date | 1995-05-04 |
- ETF.com•10 days ago
Least Popular ETFs Of The Year
It may be surprising to hear that in a year in which ETFs are shattering all sorts of records with regard to the amount of money they are taking in, the world's largest exchange-traded fund isn't participating in the bonanza. That's right; the SPDR S&P 500 ETF Trust (SPY), the $242 billion behemoth, has actually had net outflows this year to the tune of $4.2 billion.
- Market Realist•15 days ago
How Are Bioverativ’s Key Drugs Positioned after 2Q17?
In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.
- Market Realist•21 days ago
How Did United Therapeutics’ Orenitram and Unituxin Perform in 2Q17?
In 2Q17, United Therapeutics’ (UTHR) Unituxin generated revenues of around $16 million, a 10% decline on a year-over-year (or YoY) basis and an 11% decline on a quarter-over-quarter basis.
